麻豆传媒

Latest 麻豆传媒 from: Yale Cancer Center/Smilow Cancer Hospital

Filters close
麻豆传媒: William K. Oh, MD, Joins Yale Cancer Center and Smilow Cancer Hospital
Released: 5-Nov-2024 9:40 AM EST
William K. Oh, MD, Joins Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center/Smilow Cancer Hospital

William K. Oh, MD, has been appointed as Medical Director of Smilow Cancer Hospital at Greenwich Hospital, as well as Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital.

Released: 28-Oct-2024 1:50 PM EDT
Living Flat: Study Sheds Light on Challenges for Women of Color After Breast Cancer Surgery
Yale Cancer Center/Smilow Cancer Hospital

A new study led by Yale Cancer Center researchers at Yale School of Medicine titled, "Living Flat: Stories from Women of Color After Mastectomy," explains how cultural factors, spirituality, and personal beliefs play an important role in the lives of women of color after mastectomies.

麻豆传媒: Yale Cancer Center Expert to Receive Kidney Cancer Association's Rising Star Award
Released: 25-Oct-2024 2:50 PM EDT
Yale Cancer Center Expert to Receive Kidney Cancer Association's Rising Star Award
Yale Cancer Center/Smilow Cancer Hospital

Dr. David Braun, a medical oncologist at Yale Cancer Center, will be awarded the Christopher G. Wood Rising Star Award by the Kidney Cancer Association at November's International Kidney Cancer Symposium.

Released: 3-Oct-2024 11:05 AM EDT
Study Reveals Disparities in Colorectal Cancer Screening
Yale Cancer Center/Smilow Cancer Hospital

Significantly more younger people underwent colorectal cancer screening after the recommended age to begin such screening was lowered, Yale researchers report. In a new study of 10 million insured people aged 45 to 49, researchers found that a recommendation by the United States Preventative Services Task Force to drop the age for starting colorectal cancer screening by five years to age 45 was highly effective 鈥 tripling the rate of screening overall 鈥 but the magnitude of increase was significantly smaller for low-income and rural populations.

麻豆传媒: New Barcode Technology Could Help Diagnose Cancer More Precisely
Released: 30-Sep-2024 11:05 AM EDT
New Barcode Technology Could Help Diagnose Cancer More Precisely
Yale Cancer Center/Smilow Cancer Hospital

A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.

Released: 24-Sep-2024 12:05 PM EDT
Is Comprehensive Genetic Testing Worth It for Patients with Cancer?
Yale Cancer Center/Smilow Cancer Hospital

Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny 鈥 as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are conclusions of Yale medical experts who studied both and published a report in the Journal of the National Cancer Institute on Sept.

Released: 17-Sep-2024 11:05 AM EDT
Advanced 3D Mammography Detects More Breast Cancers, Fewer False Positives
Yale Cancer Center/Smilow Cancer Hospital

The newer, 3D form of breast screening, known as digital breast tomosynthesis (DBT), is more effective at detecting breast cancer than traditional 2D digital mammography (DM). That鈥檚 the conclusion of an analysis of 13 years鈥 worth of screening data conducted by Yale Cancer Center researchers.

Released: 9-Aug-2024 5:05 PM EDT
Botanical medicine reduces rectal cancer treatment side effects that can sideline surgeries
Yale Cancer Center/Smilow Cancer Hospital

Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness.

Released: 31-Jul-2024 4:05 PM EDT
Treatment for Recurrent Uterine Cancer Advances to Next Research Phase
Yale Cancer Center/Smilow Cancer Hospital

The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.

麻豆传媒: Yale New Haven Hospital nationally ranked in 11 specialties by U.S. 麻豆传媒 & World Report
Released: 17-Jul-2024 9:05 AM EDT
Yale New Haven Hospital nationally ranked in 11 specialties by U.S. 麻豆传媒 & World Report
Yale Cancer Center/Smilow Cancer Hospital

In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50).

麻豆传媒: Yale Scientists Develop Potential Stealth Cancer Therapy
Released: 15-Jul-2024 3:05 PM EDT
Yale Scientists Develop Potential Stealth Cancer Therapy
Yale Cancer Center/Smilow Cancer Hospital

Sneaking by cancer鈥檚 defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM).

Released: 20-Jun-2024 1:05 PM EDT
Chemotherapy Before Surgery Benefits Some Patients with Pancreatic Cancer
Yale Cancer Center/Smilow Cancer Hospital

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.

Released: 30-May-2024 3:05 PM EDT
Promising New Treatment for Patients with HR+ HER-2 Negative Metastatic Breast Cancer
Yale Cancer Center/Smilow Cancer Hospital

New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.

麻豆传媒: e4e6ee65-c6e0-40ad-a27d-f6865b8c377d
Released: 29-May-2024 11:05 AM EDT
A Promising New Targeted Therapy for Patients with Metastatic Prostate Cancer with Therapy-Resistant Mutations
Yale Cancer Center/Smilow Cancer Hospital

Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.

麻豆传媒: 8d050f29-dcb2-4255-8b46-ab0a8523d4ed
Released: 29-May-2024 11:05 AM EDT
Reducing Radiation After Surgery Prolongs Survival for Some Patients With HPV-Related Throat Cancer
Yale Cancer Center/Smilow Cancer Hospital

Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.

Released: 24-May-2024 11:05 AM EDT
New Survival Data From a Lung Cancer Study to be Revealed by Yale Cancer Center Expert at International Conference
Yale Cancer Center/Smilow Cancer Hospital

鈥淭he COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,鈥 explained Dr. Herbst, who will present the findings at ASCO.



close
0.13017